Intel has a Gaudi problem on its hands – the chipmaker revealed that its AI accelerator won’t even make $500 million in 2024. read more
The comment comes at a time when companies like Microsoft, Apple and Meta are banking on the AI buzz. read more
ESSA Pharma terminates its Phase 2 masofaniten trial in prostate cancer after interim data shows no added efficacy over enzalutamide alone, shifting focus to other priorities. read more
LYB shares down after reporting Q3 results below expectations. Higher feedstock costs and seasonality may impact Q4. read more
The SEC charged JPMorgan in five separate enforcement actions for failures including misleading disclosures to investors. read more
Novo Nordisk’s ESSENCE trial of semaglutide 2.4 mg shows significant improvements in liver fibrosis and steatohepatitis outcomes, with regulatory filings planned for 2025. read more
Latest Ratings for BORR Date Firm Action From To Jun 2020 Citigroup Maintains Neutral Apr 2020 BTIG Downgrades Buy Neutral Mar 2020 Citigroup Maintains Neutral View More Analyst Ratings for BORR View the Latest Analyst Ratings read more
Magna International’s Q3 earnings miss prompts plans to resume share buybacks in Q4, while shares rise in premarket trading. read more
Bitcoin’s (CRYPTO: BTC) continued its volatile trading action around the $70,000 mark on Friday morning as traders and analysts try to pin down key support and resistance levels. read more